We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+2.52%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$7.16B
AUM Growth
+$666M
(+10%)
Cap. Flow
+$831M
Cap. Flow
% of AUM
11.61%
Top 10 Holdings %
Top 10 Hldgs %
17.05%
Holding
983
New
189
Increased
207
Reduced
145
Closed
240
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$146M |
| 2 |
Gilead Sciences
GILD
|
+$116M |
| 3 |
Amazon
AMZN
|
+$86.4M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$84.7M |
| 5 |
Analog Devices
ADI
|
+$80M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$73.2M |
| 2 |
Palo Alto Networks
PANW
|
+$59.8M |
| 3 |
Alkermes
ALKS
|
+$55.3M |
| 4 |
Accenture
ACN
|
+$53.8M |
| 5 |
Johnson & Johnson
JNJ
|
+$53M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 36.05% |
| 2 | Technology | 29.2% |
| 3 | Financials | 8.76% |
| 4 | Industrials | 7.7% |
| 5 | Communication Services | 4.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Fortive
FTV
$18B
| $16.7M | 0.23% |
380,830
-318,952
| -46% | -$14.9M |
|
127
Evolent Health
EVH
$353M
| $16.7M | 0.23% |
464,761
+357,864
| +335% | +$12.6M |
|
128
DXC Technology
DXC
$1.75B
| $16.5M | 0.23% |
674,834
+653,552
| +3,071% | +$18M |
|
129
Expedia Group
EXPE
$35.8B
| $16.5M | 0.23% |
+175,852
| New | +$17.9M |
|
|
RXDX
130
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $16.4M | 0.23% |
277,737
-913,924
| -77% | -$41.8M |
|
|
JNPR
131
DELISTED
Juniper Networks
JNPR
| $16.2M | 0.23% |
619,491
-46,581
| -7% | -$1.31M |
|
132
Zscaler
ZS
$26.4B
| $16.1M | 0.22% |
+97,892
| New | +$16M |
|
133
On Holding
ONON
$12.6B
| $16.1M | 0.22% |
1,000,020
-321,378
| -24% | -$6.41M |
|
134
Nice
NICE
$5.9B
| $15.9M | 0.22% |
84,230
+34,872
| +71% | +$7.28M |
|
135
Zai Lab
ZLAB
$2.05B
| $15.8M | 0.22% |
463,329
-183,933
| -28% | -$7.87M |
|
|
NVRO
136
DELISTED
NEVRO CORP.
NVRO
| $15.8M | 0.22% |
338,790
-154,951
| -31% | -$7.19M |
|
137
Intel
INTC
$509B
| $15.6M | 0.22% |
+606,974
| New | +$20.7M |
|
138
Arista Networks
ANET
$240B
| $15.6M | 0.22% |
553,200
+45,596
| +9% | +$1.31M |
|
|
MRTX
139
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $15.5M | 0.22% |
222,508
-71,059
| -24% | -$5.26M |
|
|
DVAX
140
DELISTED
Dynavax Technologies
DVAX
| $15.4M | 0.22% |
1,476,266
+389,383
| +36% | +$5.07M |
|
|
CERE
141
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $15.2M | 0.21% |
536,385
+280,852
| +110% | +$8.36M |
|
142
UnitedHealth
UNH
$370B
| $15.1M | 0.21% |
+29,842
| New | +$15.7M |
|
143
Pentair
PNR
$10.9B
| $15M | 0.21% |
368,331
-156,339
| -30% | -$7.25M |
|
144
Boeing
BA
$185B
| $14.9M | 0.21% |
123,156
-52,253
| -30% | -$8.01M |
|
|
SJR
145
DELISTED
Shaw Communications Inc.
SJR
| $14.9M | 0.21% |
611,002
-35,000
| -5% | -$927K |
|
146
Xenon Pharmaceuticals
XENE
$6.02B
| $14.6M | 0.2% |
404,359
+175,431
| +77% | +$6.31M |
|
|
COWN
147
DELISTED
Cowen Inc. Class A Common Stock
COWN
| $14.5M | 0.2% |
+374,739
| New | +$13.6M |
|
|
OLK
148
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $14.2M | 0.2% |
1,167,962
+109,282
| +10% | +$1.68M |
|
149
Home Depot
HD
$339B
| $14.1M | 0.2% |
51,259
-13,474
| -21% | -$3.98M |
|
150
Intuitive Surgical
ISRG
$130B
| $14.1M | 0.2% |
75,000
-120,324
| -62% | -$25.8M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q3 2022 Portfolio in Review
As of Q3 2022, Woodline Partners held 983 positions worth $7.16B, up 10% from $6.49B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Woodline Partners deployed $831M of net new capital in Q3 2022, opening 189 new positions and adding to 207 existing holdings. Its largest new stake was Amazon: 683,398 shares worth $77.2M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 35% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $73.2M trimmed.
- Woodline Partners's largest Q3 2022 buy was Amazon: 683,398 shares worth $77.2M.
- Woodline Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, an estimated $146M increase.
- Woodline Partners's biggest Q3 2022 reduction was Eli Lilly, cutting an estimated $73.2M.
- Woodline Partners fully exited Palo Alto Networks in Q3 2022, selling an estimated $59.8M.
- Woodline Partners's ten largest holdings make up 17% of its $7.16B portfolio in Q3 2022.
- Woodline Partners opened 189 new positions and closed 240 in Q3 2022.
- Woodline Partners's portfolio value rose 10% quarter-over-quarter to $7.16B.
Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.